Literature DB >> 17426170

Characterization of natural antimony resistance in Leishmania donovani isolates.

Mukul K Mittal1, Smita Rai, Suman Gupta, Shyam Sundar, Neena Goyal.   

Abstract

Clinical resistance to pentavalent antimonial compounds has long been recognized as a major problem in the treatment of visceral leishmaniasis in India. However, mechanisms of natural resistance are unclear. In this study, we observed that Leishmania donovani clinical isolates not responsive to sodium stibogluconate showed resistance to antimony treatment in both in vitro and in vivo laboratory conditions. The resistant isolates have increased levels of intracellular thiols. This increase in thiol levels was not mediated by the amplification of gamma-glutamylcysteine synthetase, but was accompanied by amplification of trypanothione reductase and an intracellular ATP-binding cassette transporter gene MRPA. The resistance of parasites to antimony could be reversed by the glutathione biosynthesis-specific inhibitor, buthionine sulfoximine, which resulted in increased drug susceptibility. These results suggest the possible role of thiols and MRPA in antimony resistance in field isolates.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17426170

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  51 in total

1.  Biomarkers of antimony resistance: need for expression analysis of multiple genes to distinguish resistance phenotype in clinical isolates of Leishmania donovani.

Authors:  Dhiraj Kumar; Ruchi Singh; Vasundhra Bhandari; Arpita Kulshrestha; Narendra Singh Negi; Poonam Salotra
Journal:  Parasitol Res       Date:  2012-07       Impact factor: 2.289

2.  Downregulation of mitogen-activated protein kinase 1 of Leishmania donovani field isolates is associated with antimony resistance.

Authors:  Mansi Garg; Shyam Sundar; Robert Duncan; Hira L Nakhasi; Neena Goyal
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

3.  MAPK1 of Leishmania donovani modulates antimony susceptibility by downregulating P-glycoprotein efflux pumps.

Authors:  Mansi Garg; Neena Goyal
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

Review 4.  Antimony transport mechanisms in resistant leishmania parasites.

Authors:  Frédéric Frézard; Rubens Monte-Neto; Priscila G Reis
Journal:  Biophys Rev       Date:  2014-01-25

5.  Cross-resistance of Leishmania infantum isolates to nitric oxide from patients refractory to antimony treatment, and greater tolerance to antileishmanial responses by macrophages.

Authors:  Tatiana R de Moura; Micheli Luize Barbosa Santos; Juciene M Braz; Luis Felipe V C Santos; Matheus T Aragão; Fabricia A de Oliveira; Priscila L Santos; Ângela Maria da Silva; Amélia Ribeiro de Jesus; Roque P de Almeida
Journal:  Parasitol Res       Date:  2016-02       Impact factor: 2.289

Review 6.  DNA repair pathways in trypanosomatids: from DNA repair to drug resistance.

Authors:  Marie-Michelle Genois; Eric R Paquet; Marie-Claude N Laffitte; Ranjan Maity; Amélie Rodrigue; Marc Ouellette; Jean-Yves Masson
Journal:  Microbiol Mol Biol Rev       Date:  2014-03       Impact factor: 11.056

7.  Frequency of MDR1-related p-gp overexpression in Greek Leishmania isolates.

Authors:  Johannes Austrup; Pantelis Ntais; Vasiliki Christodoulou; Jean-Pierre Dedet; Francine Pratlong; Maria Antoniou
Journal:  Parasitol Res       Date:  2014-02-07       Impact factor: 2.289

8.  Oral azithromycin versus its combination with miltefosine for the treatment of experimental Old World cutaneous leishmaniasis.

Authors:  Eglal I Amer; Maha M Eissa; Shereen F Mossallam
Journal:  J Parasit Dis       Date:  2014-08-31

9.  Antimony resistance and trypanothione in experimentally selected and clinical strains of Leishmania panamensis.

Authors:  Diego A Goyeneche-Patino; Liliana Valderrama; John Walker; Nancy G Saravia
Journal:  Antimicrob Agents Chemother       Date:  2008-09-29       Impact factor: 5.191

Review 10.  Drug resistance in visceral leishmaniasis.

Authors:  Helena C Maltezou
Journal:  J Biomed Biotechnol       Date:  2009-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.